IGF-1 LR3

IGF-1 LR3 is short for Long R3 insulin-like growth factor 1, a redesigned copy of a hormone your own liver and muscles already make. The natural version, insulin-like growth factor 1, is the messenger that growth hormone largely works through. An Australian laboratory rebuilt it in 1992 by swapping one building block (glutamate at position 3 became arginine, which is what the R3 stands for) and bolting a 13-unit tail onto the front, taken from the first 11 amino acids of pig growth hormone plus two extra residues (Francis 1992). The point of those changes was to stop the molecule sticking to its carrier proteins, the insulin-like growth factor binding proteins, so that more of it reaches receptors. It was made as a laboratory tool and cell-culture supplement, and that remains its only sanctioned use: it has never been approved for human use anywhere, and the anti-doping laboratories that study it describe the material sold for bodybuilding as a black market product (Mongongu 2021).

• Sold and used off-label for muscle growth and strength, which is why most people look it up; no study in people has tested that use
• As a cell-culture supplement in laboratories, standing in for insulin in serum-free media, which is what the molecule was designed for
• In animal research as a tool for studying how insulin-like growth factor 1 behaves when it is not bound up by its carrier proteins (Francis 1992)
• In fetal-growth and veterinary research, where it has been infused into sheep, rats and guinea pigs to test whether it can drive growth (Rozance 2021; White 2025)
• As a reference substance in anti-doping laboratories building tests to catch it in athlete samples (Mongongu 2021)

Think of natural insulin-like growth factor 1 as a courier that spends almost all its time handcuffed to escorts, the binding proteins, which decide when and where it gets released. IGF-1 LR3 is the same courier redesigned so the handcuffs will not clip on, so it walks straight up to the receptor. That sounds like a pure upgrade, but the escorts were also what kept the courier in circulation and pointed it at the right door. In cells that make no binding proteins at all, the redesigned version is actually less potent than the original, which tells you the advantage comes from dodging the escorts rather than from being a better key (Francis 1992).

1. First hoursThe only in vivo pharmacokinetic data located come from rats given a single intramuscular dose: the unchanged molecule disappeared rapidly after about 4 hours, while a breakdown product was still detectable at 16 hours (Mongongu 2021). The 20-plus-hour half-life figure that circulates online was not found in any study located.
2. Week 1One week of continuous infusion is the commonest design in the animal literature. In normal fetal sheep it raised heart, adrenal and spleen weights without raising overall body weight, and lowered circulating insulin (Rozance 2021).
3. Weeks 2-4No study located ran anything resembling the daily post-training injection schedule people use, so the literature supports no expectation at all for this window.
4. Beyond 4 wksThe longest exposure located in any animal study is roughly one week of infusion. Nothing published describes what a four-week cycle does, in animals or in people.
5. Long termThere is no long-term data in any species and none at all in humans. Anything you read about lasting gains in muscle fibre number is extrapolation rather than a measured result.

• No human trial of IGF-1 LR3 was located, so there is no adverse-event table for this molecule. What follows comes from the approved insulin-like growth factor 1 product and from the animal work, and the absence of human data is itself the main finding.
• Falling blood sugar is the consistent concern across this class. The United States prescribing information for mecasermin (Increlex), the approved recombinant human insulin-like growth factor 1 product, reports hypoglycaemia in 42 percent of the 71 children studied, with 5 severe episodes and 4 involving seizure or loss of consciousness
• Enlargement of lymphoid tissue appears on that same label: tonsillar hypertrophy in 15 percent of those children, alongside snoring and middle-ear problems
• That label also carries warnings for allergic reactions including anaphylaxis, raised pressure inside the skull, slipped capital femoral epiphysis, worsening scoliosis and malignant neoplasia, and contraindicates the drug in anyone with malignant neoplasia or closed growth plates
• Insulin suppression has been measured for IGF-1 LR3 itself: a week of infusion lowered circulating insulin in fetal sheep (Rozance 2021), and in a second sheep study circulating amino acid concentrations fell during treatment (White 2025)
• Injection-site reactions such as lipohypertrophy and bruising are reported for injected insulin-like growth factor 1 products and are a predictable consequence of repeated subcutaneous dosing
• Product quality is a hazard of its own. Anti-doping chemists analysing black market insulin-like growth factor 1 analogue products found abundant oxidised, lower-quality peptide forms, enough that their assay had to monitor the oxidised species as well as the native one (Mongongu 2021)

• You are pregnant, trying to conceive, or breastfeeding; the only work on this analogue in pregnancy is animal fetal-growth research and it does not support human use
• You have a current, past or suspected cancer, or a family history your doctor is concerned about; the approved insulin-like growth factor 1 product is contraindicated in malignant neoplasia, and this is the class's clearest red line
• You have diabetes or take insulin or any glucose-lowering medicine, because the documented headline adverse effect of this class is hypoglycaemia and it can be severe
• You are under 18 or your growth plates have not closed; the approved product is contraindicated once epiphyses are closed, and its paediatric warnings include slipped capital femoral epiphysis and progression of scoliosis
• You compete under the World Anti-Doping Agency code; insulin-like growth factor 1 and its analogues, LongR3-IGF-I named explicitly, are prohibited at all times (Mongongu 2021)
• You are not under the supervision of a physician who knows you are using it, can check your blood glucose, and can act if it drops

• Treating the 20-plus-hour half-life claim as established. The one in vivo pharmacokinetic dataset located found the unchanged molecule cleared rapidly after about 4 hours in rats, and the 1996 rat work states plainly that low binding-protein affinity makes it clear from the circulation faster than natural insulin-like growth factor 1, not slower (Mongongu 2021; Tomas 1996).
• Expecting hyperplasia, meaning new muscle fibres. No study located measured an increase in muscle fibre number with IGF-1 LR3. What the animal work repeatedly shows instead is disproportionate growth of gut, kidney, spleen, adrenals and heart, often with no increase in whole-body weight at all (Conlon 1995; Rozance 2021).
• Dosing with no way to check blood sugar. Hypoglycaemia is the documented headline risk for this class, it can be severe, and fasted or post-training dosing is the situation most likely to provoke it.
• Assuming research-grade material is pharmaceutical-grade. Analysis of black market insulin-like growth factor 1 analogue products found substantial oxidised and degraded peptide (Mongongu 2021), and this molecule is manufactured and sold as a cell-culture reagent rather than as a drug.
• Reconstituting or storing it carelessly. Use bacteriostatic water, run it down the inside wall of the vial rather than jetting it onto the powder, swirl instead of shaking, keep the powder cold and dark, and refrigerate after reconstitution.
• Stacking it with growth hormone or a growth hormone secretagogue on the assumption that the effects add up. Growth hormone already works largely through insulin-like growth factor 1, and no study located has examined that combination.